These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25196718)

  • 1. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.
    Kumada H; Sato K; Takehara T; Nakamuta M; Ishigami M; Chayama K; Toyota J; Suzuki F; Nakayasu Y; Ochi M; Yamada I; Okanoue T
    Hepatol Res; 2015 Jul; 45(7):745-54. PubMed ID: 25196718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey.
    Aygen B; Yıldız O; Akhan S; Çelen MK; Ural O; Koruk ST; Köse Ş; Korkmaz F; Kuruüzüm Z; Tuna N; Taheri S; Sayan M; Demir NA; Sümer Ş; Altınok ES
    Balkan Med J; 2015 Jul; 32(3):266-72. PubMed ID: 26185714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.
    Shimada N; Tsubota A; Atsukawa M; Abe H; Ide T; Takaguchi K; Chuganji Y; Toyoda H; Yoshizawa K; Ika M; Sato Y; Kato K; Kumada T; Sakamoto C; Aizawa Y; Sata M
    Hepatol Res; 2014 Dec; 44(14):E386-96. PubMed ID: 24606109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study.
    Kumada H; Hayashi N; Izumi N; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Rito K; Komada Y; Seto C; Goto S
    Hepatol Res; 2015 May; 45(5):501-13. PubMed ID: 24961662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
    Asselah T
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):455-62. PubMed ID: 23199504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.
    Virlogeux V; Pradat P; Bailly F; Funingana G; Gonçalves F; Maynard M; Hartig-Lavie K; Amiri M; Zoulim F
    J Viral Hepat; 2014; 21(9):e98-e107. PubMed ID: 24612466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients.
    Kumada H; Suzuki F; Kamiya N; Orihashi M; Nakayasu Y; Yamada I
    Hepatol Res; 2017 May; 47(6):514-521. PubMed ID: 27062488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.
    Ueda T; Tsuchiya K; Hashimoto S; Inoue T; Enomoto N; Inao M; Tanaka A; Kaito M; Imazeki F; Nishiguchi S; Mochida S; Yokosuka O; Yatsuhashi H; Izumi N; Kudo M;
    Dig Dis; 2012; 30(6):554-60. PubMed ID: 23258094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
    Wedemeyer H; Forns X; Hézode C; Lee SS; Scalori A; Voulgari A; Le Pogam S; Nájera I; Thommes JA
    PLoS One; 2016; 11(1):e0145409. PubMed ID: 26752189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection.
    Ogawa E; Furusyo N; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Nakamuta M; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    Antiviral Res; 2014 Apr; 104():102-9. PubMed ID: 24462955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
    Kumada H; Toyota J; Okanoue T; Chayama K; Tsubouchi H; Hayashi N
    J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype.
    Abe H; Tsubota A; Shimada N; Atsukawa M; Kato K; Takaguchi K; Asano T; Chuganji Y; Sakamoto C; Toyoda H; Kumada T; Ide T; Sata M; Aizawa Y
    Hepatol Res; 2015 Apr; 45(4):387-96. PubMed ID: 24849518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
    Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
    Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
    Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
    Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
    J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
    Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
    J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.